Related Experiment Video
Updated: Mar 26, 2026
07:25
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
18.3K
The economic implications of biosimilars.
Surya C Singh1, Karen M Bagnato
1surya.singh@cvshealth.com.
The American Journal of Managed Care
|January 21, 2016
Summary
Spending on biologics is rapidly increasing, with biosimilars expected to offer cost savings. Healthcare providers should evaluate the economic impact of adopting these biologic alternatives.
Area of Science:
- Pharmaceutical Economics
- Biotechnology
- Drug Development
Background:
- Specialty drug spending, particularly on biologics, significantly outpaced small-molecule drugs between 2013-2014.
- Biologics are projected to dominate the top-selling drug market by 2016.
- Upcoming patent expirations for biologics will pave the way for biosimilar development.
Purpose of the Study:
- To analyze the economic implications of biosimilar adoption.
- To assess the potential cost-effectiveness of biosimilars in clinical practice.
- To inform managed care providers about the financial impact of biosimilars.
Main Methods:
- Analysis of drug spending trends.
- Review of projected market share for biologics.
- Evaluation of regulatory considerations for biosimilars.
Main Results:
- Biologic drug spending increased by 32.4% from 2013-2014.
- Biosimilars are anticipated to reduce drug costs, though less dramatically than small-molecule generics.
- Multiple manufacturers are expected to enter the biosimilar market.
Conclusions:
- Biosimilar development presents a significant opportunity for healthcare cost savings.
- Managed care clinicians must carefully consider the economic benefits of integrating biosimilars.
- Regulatory frameworks are crucial for ensuring biosimilar safety and efficacy.
Related Concept Videos
01:28Drug Products: Biologics, Biosimilars and Interchangeables
352
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
352
01:16Bioequivalence: Overview
2.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.2K
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
216
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
216
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
240
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
240
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
71
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
71
01:26Pharmaceutical Equivalents
259
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
259